JP2012528152A - バークホルデリア汚染菌株によって産生される独特の抗真菌糖ペプチドのオシジオファンジン - Google Patents
バークホルデリア汚染菌株によって産生される独特の抗真菌糖ペプチドのオシジオファンジン Download PDFInfo
- Publication number
- JP2012528152A JP2012528152A JP2012513041A JP2012513041A JP2012528152A JP 2012528152 A JP2012528152 A JP 2012528152A JP 2012513041 A JP2012513041 A JP 2012513041A JP 2012513041 A JP2012513041 A JP 2012513041A JP 2012528152 A JP2012528152 A JP 2012528152A
- Authority
- JP
- Japan
- Prior art keywords
- antifungal
- compound
- osidiofungin
- fungal
- naa2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
【選択図】 図1
Description
本出願書類は、2009年5月26日付で出願された米国暫定特許出願第61/217,026の優先権を請求するものである。この暫定特許出願の全体は、この参照により本明細書に組み込まれる。
本発明は、米農務省(USDA)の共同研究教育普及局(Cooperative State Research, Education, and Extension Service)から授与された0204332の政府支援により行われた。米国政府は本発明に特定の権利を有する。
本発明は、真菌感染および疾患の予防または治療における、抗真菌化合物およびその治療上の利用の分野に関する。本発明は、動植物に対する薬学および農学的殺真菌薬としての新規抗真菌化合物の利用に関する。本発明はさらに、新規抗真菌化合物を産生する細菌菌株に関する。
すべての化学物質はSigma(ミズーリ州St. Louis)から購入し、特に記載のない限り、最高グレードのものとした。オシジオファンジンは前述の通り産生および精製した。
オシジオファンジンは環状糖ペプチドである。高解像度質量分析データからは、抗真菌ペプチドには2つの構造変異体があることが明らかとなり、1つはモノアイソトピック質量1,199.543Da、もう1つはモノアイソトピック質量1,215.518Daであり、これは最初の化合物に酸素を足した構造に相当する。これらの質量は、図1に示し、解明された構造と一致している(モノアイソトピック質量の計算値は1,199.5584と1,215.5533)。2つの構造変異体があることを考え、抗真菌化合物の変異体はオシジオファンジンA(1,199.5584Da)およびオシジオファンジンB(1,215.5533Da)と呼ぶ。標準的な衝突エネルギーではグリカンが失われるだけで、前記抗真菌化合物を断片化するために必要な高い衝突エネルギーによって、複雑な一連の娘イオンが生成するため、抗真菌化合物のESI−TOF MS/MS分析の結論は得られていない。しかし、断片化が起こるために高い解離エネルギーが必要であったことは、前記化合物が環状ペプチドであることを示唆している。標準的な解離方法では、親イオンから149Daが消失するだけであり、これはペントース糖があることを示している。GC分析では、オリゴペプチドに結合した前記糖がキシロースであることが明らかとなった(図2)。すでに報告されているとおり、アミノ酸分析ではリジンがあることが明らかとなっている。しかし、前記ペプチドをトリプシン消化しようとする試みは成功せず、これはおそらく、前記化合物の特殊な構造上の特徴のためであろう(データは図示せず)。前記抗真菌ペプチドを線状化することができないため、その後のESI−MS分析もできなかった。
本研究の所見は、新規アミノ酸を含むオシジオファンジンの全共有構造が解明されたこと、オシジオファンジンの広域スペクトルの抗真菌活性の特徴が決定されたこと、前記抗真菌化合物処理後に細胞封入体および膜が不安定になるというin vivo所見が得られたことなどである。
Cook,R.R.,and Baker,K.F.(1983) The nature and practice of biological control of plant pathogens.American Phytopathological Society,St.Paul,MN.
Lu,S−E.,Woolfolk,S.,and Caceres,J.(2005) Isolation and identification and genetic analysis of rhizobacteria antagonistic to plant soilborne fungal pathogens.Phytopathology 95,62−63.
Gu,G.Y.,Smith,L.,Wang,N.,Wang,H.,and Lu,S−E.(2009) Biosynthesis of an antifungal oligopeptide in Burkholderia contaminans strain MS 14.Biochem.Biophys.Res.Commun.380,328−332.
Gu,G.,Wang,N.,Chaney,N.,Smith,L.,and Lu,S−E.(2009) AmbRl is a key transcriptional regulator for production of antifungal activity of Burkholderia contaminans strain MS14.FEMS Microbiol.Lett.Accepted May 5,2009.
Ghannoum,M.G.,and Rice,L.B.(1999) Antifungal Agents: Mode of Action,Mechanisms of Resistance,and Correlation of these Mechanisms with Bacterial Resistance.Clin.Microbiol.Rev.12,501 −517.
Kavanagh,K.(2007) New Insights in Medical Mycology,Springer,New York,NY.
Lorian,V.(2005),Antibiotics in laboratory medicine,Lippincott Williams & Wilkins,Philadelphia,PA.Hashimoto,S.(2009) Micafungin: a sulfated echinocandin.J.Antibiot.62,27−35.
Dceda,F.,Tanaka,S.,Ohki,H.,Matsumoto,S.,Maki,K.,Katashima,M.,Barrett,D.,and Aoki,Y.(2007) Role of micafungin in the antifungal armamentarium.Curr.Medic.Chem.14,1263−1275.de Groot,P.W.J.,de Boer,A.D.,Cunningham,J.,Dekker,H.L.,de Jong,L.,Hellingwerf,K.J.,de Koster,C,and Klis,F.M.(2004) Proteomic analysis of Candida albicans cell walls reveals covalently bound carbohydrate−active enzymes and adhesins.Eukaryot.Cell 3,955−965.
Klis,F.M.,de Groot,P.,and Hellingwerf,K.(2001) Molecular organisation of the cell wall of Candida albicans.Med.Mycol.39,1−8.
Munro,C.A.and Gow,N.A.R.(2001) Chitin synthesis in human pathogenic fungi.Med.Mycol.39,41−53.
Roncero,C.(2002) The genetic complexity of chitin synthesis in fungi.Curr.Genet.41,367−378.
Douglas,C.M.,D'Ippolito,J.A.,Shei,G.J.,Meinz,M.,Onishi,J.,Marrinan,J.A.,Li,W.,Abruzzo,G.K.,Flattery,A.,Bartizal,K.,Mitchell,A.,and Kurtz,M.B.(1997) Identification of the FKSl gene of Candida albicans as the essential target of 1 ,3−beta−D−glucan synthase inhibitors.Antimicrob.Agents Chemother.41,2471−2479.
Chiarini,L.,Bevivino,A.,Dalmastri,C,Tabacchioni,S.,and Visca,P.(2006) Burkholderia cepacia complex species: health hazards and biotechnological potential.Trends Microbiol.14,277−286.
Mahenthiralingam,E.,Baldwin,A.,and Dowson,C.G.(2008) Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology.J.Appl.Microbiol.104,1539−1551.
Walker,L.A.,Munro,C.A.,de Bruijn,I.,Lenardon,M.D.,McKinnon,A.,and Gow,N.A.R.(2008) Stimulation of chitin synthesis rescues Candida albicans from echinocandins.PIoS Pathog.4(4),el000040.
Nishiyama,Y.,Hasumi,Y.,Ueda,K.,Uchida,K.,and Yamaguchi,H.(2005) Effects of micafungin on the morphology of Aspergillus fumigatus.J.Electron Microsc.54,67−77.
Nakai,T.,Hatano,K.,Ikeda,F.,and Shibuya,K.(2005) Electron microscopic findings for micafungin−treated experimental pulmonary aspergillosis in mice.Med.Mycol.43,439−445.
Angiolella,L.,Maras,B.,Stringaro,A.R.,Arancia,G.,Mondello,F.,Girolamo,A.,Palamara,A.T.,and Cassone,A.(2005) Glucan−associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin,a water−soluble,lipopeptide antimycotic.J.Chemother.17,409−416.Tomana,M.,Prchal,J.,Garner,L.,Skalka,H.,and Barker,S.(1984) Gas chromatographic analysis of lens monosaccharides.J.Lab.Clin.Med.103,137−142.
Renfrow,M.B.,Cooper,H.J.,Tomana,M.,Kulhavy,R.,Hiki,Y.,Toma,K.,Emmett,M.R.,Mestecky,J.,Marshal,A.G.,and Novak,J.(2005) Determination of aberrant O−glycosylation in the IgAl hinge region by electron capture dissociation Fourier transform−ion cyclotron resonance mass spectrometry.J.Biol.Chem.280,19136−19145.
Wuthrich,K.(1986) NMR of Proteins and Nucleic Acids.Wiley,New York.
Braunschweiler,L.,and Ernst,R.R.(1983) Coherence Transfer By Isotropic Mixing −Application to Proton Correlation Spectroscopy.J.Magn.Reson.53,521−528.
Kumar,A.,Ernst,R.R.,and Wuthrich,K.(1980) A Two−Dimensional Nuclear Overhauser Enhancement (2D NOE) Experiment for the Elucidation of Complete Proton−Proton Cross−Relaxation Networks in Biological Macromolecules.Biochem.Biophys.Res.Commun.95,1−6.
Bothner−By,A.A.,Stephens,R.L.,Lee,J.,Warren,C.D.,and Jeanloz,R.W.(1984) Structure determination of a tetrasaccharide: transient nuclear Overhauser effects in the rotating frame.J.Am.Chem.Soc.106,811−813.Bodenhausen,G.,and Ruben,D.J.(1980) Natural abundance nitrogen− 15 NMR by enhanced heteronuclear spectroscopy.Chem.Phys.Lett.69,185−188.
Hwang,T.L.,and Shaka,A.J.(1995) Water suppression that works.Excitation sculpting using arbitrary waveforms and pulsed field gradients.J.Magn.Reson.Al 12,275−279.
Dalvit,C.(1998) Efficient multiple−solvent suppression for the study of the interactions of organic solvents with biomolecules.J.Biomol.NMR.SLl,437−444.Shaka,A.J.,Lee,C.J.,and Pines,A.(1988) Iterative Schemes for Bilinear Operators − Application to Spin Decoupling.J.Magn.Reson.77,274−293.
Marion,D.,Dαira,M.,Tschudin,R.,and Bax,A.(1989) Rapid Recording of 2D NMR−Spectra without Phase Cycling − Application to the Study of Hydrogen−Exchange in Proteins.J.Magn.Reson.85,393−399.Kay,L.E.,Keiffer,P.,and Saarinen,T.(1992) Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity.J.Am.Chem.Soc.114,10663−10665.
Boban,J.K.,Plant,D.,and Hurd,R.E.(1992) Improved Proton−Detected Heteronuclear Correlation Using Gradient−Enhanced z and zz filters.J.Magn.Reson.AlOl,113.Delaglio,F.,Grzesiek,S.,Vuister,G.W.,Zhu,G.,Pfeifer,J.,and Bax,A.(1995) NMRpipe −a Multidimensional Spectral Processing System Based on Unix Pipes.J.Biomol.NMR 6,277−293.
Johnson,B.A.,and Blevins,R.A.(1994) NMR View − a Computer−Program for the Visualization and Analysis of NMR Data.J.Biomol.NMR 4,603−614.Gross,D.,and DeVay,J.(1977) Production and purification of syringomycin,a phytotoxin produced by Pseudomonas syringae.Physiol.Plant Pathol.11,13−28.
Nishiyama,Y.,Uchida,K.,and Yamaguchi,H.(2002) Morphological changes of Candida albicans induced by micafungin (FK463),a water−soluble echinocandinlike lipopeptide.J.Electron Microsc.51,247−255.Lin,S.,Liehr,S.,Cooperman,B.S.,and Cotter,R.J.(2001) Sequencing cyclic peptide inhibitors of mammalian ribonucleotide reductase by electrospray ionization mass spectrometry.J.Mass.Spectrom.36,658−663.
Frias,H.V.,Mendes,M.A.,Cardozo,K.H.M.,Carvalho,V.M.,Tomazela,D.,Colepicolo,P.,and Pinto,E.(2006) Use of electrospray tandem mass spectrometry for identification of microcystins during a cyanobacterial bloom event.Biochem.Biophys.Res.Commun.344,741−746.
Felnagle,E.A.,Jackson,E.E.,Chan,Y.A.,Podevels,A.M.,Berti,A.D.,McMahon,M.D.,and Thomas,M.G.(2008) Nonribosomal peptide synthetases involved in the production of medically relevant natural products.MoI.Pharm.5,191−211.
Waelder,S.,Lee,L.,and Redfield,A.G.(1975) Nuclear magnetic resonance studies of exchangeable protons.I.Fourier transform saturation−recovery and transfer of saturation of the tryptophan indole nitrogen proton.J.Am.Chem.Soc.97,2927−2928.
Krishnan−Natesan,S.,and Chandrasekar,P.H.(2008) Current and future therapeutic options in the management of invasive aspergillosis.Drugs 68,265−282.
Ngwogu,A.C,and Otokunefor,T.V.(2007) Epidemiology of dermatophytes in a rural community in Eastern Nigeria and review of literature from Africa.Mycopathologia 164,149−158.
Yaghmour,M.A.,Inderbitzin,P.,Bostock,R.M.,and Michailides,T.J.(2008) Characterization of Geotrichum candidum causing sour rot of peaches and nectarines in California.Phytopathology 98,Sl 75−Sl 75.Sfakianakis,A.,Krasagakis,K.,Stefanidou,M.,Maraki,S.,Koutsopoulos,A.,Kofteridis,D.,
Samonis,G.,and Tosca,A.(2007) Invasive cutaneous infection with Geotrichum candidum −sequential treatment with amphotericin B and voriconazole.Med.Mycol.45,81−84.
Pereira,D.I.B.,Santurio,J.M.,Alves,S.H.,Argenta,J.S.,Potter,L.,Spanamberg,A.,and Ferreiro,L.(2007) Caspofungin in vitro and in vivo activity against Brazilian Pythium insidiosum strains isolated from animals.J.Antimicrob.Chemother.60,1168−1171.
Argenta,J.S.,Santurio,J.M.,Alves,S.H.,Pereira,D.I.B.,Cavalheiro,A.S.,Spanamberg,A.,and Ferreiro,L.(2008) In vitro activities of voriconazole,itraconazole,and terbinafine alone or in combination against Pythium insidiosum isolates from Brazil.Antimicrob.Agents Chemother.52,767−769.Popolo,L.,Gualtieri,T.,and Ragni,E.(2001) The yeast cell−wall salvage pathway.Med.Mycol.39,111−121.
Levin,D.E.(2005) Cell wall integrity signaling in Saccharomyces cerevisiae.Microbiol.MoI.Biol.Rev.69,262−291.
Douglas,C.M.(2001) Fungal beta(l,3)−D−glucan synthesis.Med.Mycol.39,55−66.
Claims (12)
- 請求項1または2記載の抗真菌化合物において、前記アミノ酸残基NAA2は、さらに、結合したアシル基およびキシロース糖を有するものである、抗真菌化合物。
- 請求項3記載の抗真菌化合物において、前記化合物は菌性植物、動物、およびヒト病原体に対して有効である、抗真菌化合物。
- 請求項3記載の抗真菌化合物において、前記化合物は菌性植物、動物、およびヒト病原体の細胞膜形態を崩壊させるものである、抗真菌化合物。
- 請求項1または2いずれか記載の抗真菌化合物、および少なくとも1つの薬学的に許容される基材または賦形剤を有する医薬組成物。
- 請求項7記載の組成物において、少なくとも1つの基材または賦形剤は農学的に許容される基材または賦形剤である、組成物。
- 請求項5記載の抗真菌化合物において、前記化合物は真菌菌株バークホルデリア汚染菌に由来するものである、抗真菌化合物。
- 単離細菌菌株MS14であって、当該細菌菌株はバークホルデリア汚染菌種に属するものであり、その遺伝子DNA断片は配列が決定され、受入番号EU938698でGenbankに預け入れられ、前記菌株は少なくとも1つの抗真菌化合物を産生する活性を上昇させる原因となる遺伝子領域を有するものである、単離細菌菌株MS14。
- 請求項10記載の単離細菌菌株において、前記少なくとも1つの抗真菌化合物は、請求項1記載の抗真菌環状糖ペプチド化合物である、単離細菌菌株。
- 請求項10記載の単離細菌菌株において、前記少なくとも1つの抗真菌化合物は、請求項2記載の抗真菌環状糖ペプチド化合物である、単離細菌菌株。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21702609P | 2009-05-26 | 2009-05-26 | |
US61/217,026 | 2009-05-26 | ||
US12/800,922 | 2010-05-25 | ||
US12/800,922 US20110136729A1 (en) | 2009-05-26 | 2010-05-25 | Occidiofungin, a unique antifungal glycopeptide produced by a strain of burkholderia contaminans |
PCT/US2010/001530 WO2010138173A1 (en) | 2009-05-26 | 2010-05-26 | Occidiofungin, a unique antifungal glycopeptide produced by a strain of burkholderia contaminans |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012528152A true JP2012528152A (ja) | 2012-11-12 |
JP2012528152A5 JP2012528152A5 (ja) | 2013-07-18 |
Family
ID=43222997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012513041A Pending JP2012528152A (ja) | 2009-05-26 | 2010-05-26 | バークホルデリア汚染菌株によって産生される独特の抗真菌糖ペプチドのオシジオファンジン |
Country Status (11)
Country | Link |
---|---|
US (2) | US20110136729A1 (ja) |
EP (1) | EP2435060B1 (ja) |
JP (1) | JP2012528152A (ja) |
KR (1) | KR20120062644A (ja) |
CN (1) | CN102448481A (ja) |
DK (1) | DK2435060T3 (ja) |
ES (1) | ES2757855T3 (ja) |
HU (1) | HUE047339T2 (ja) |
PL (1) | PL2435060T3 (ja) |
PT (1) | PT2435060T (ja) |
WO (1) | WO2010138173A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2019124410A1 (ja) * | 2017-12-21 | 2020-05-28 | 株式会社 サティス製薬 | 化粧料用原料とこれを配合してなる皮膚用化粧料 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ587490A (en) * | 2010-08-20 | 2013-03-28 | Greentide Ltd | Anti-Microbial Compounds containing compounds with a sugar substituent |
US8785376B2 (en) | 2010-12-20 | 2014-07-22 | Virginia Tech Intellectual Properties | Isolation, identification, and uses of antifungal compounds |
WO2013096697A2 (en) * | 2011-12-20 | 2013-06-27 | University Of Utah Research Foundation | Isolation, identification, and used of antifungal compounds |
US9624270B2 (en) | 2012-11-29 | 2017-04-18 | Mississippi State University | Engineering the production of a conformational variant of occidiofungin that has enhanced inhibitory activity against fungal species |
CN104109645B (zh) * | 2014-06-06 | 2016-10-12 | 山西省农业科学院农产品贮藏保鲜研究所 | 用于防治果蔬采后病害的菌株及生防菌剂 |
EP3191114B1 (en) | 2014-09-12 | 2021-03-03 | Mississippi State University | Occidiofungin formulations and uses thereof |
US10330081B2 (en) | 2017-02-07 | 2019-06-25 | International Business Machines Corporation | Reducing curtailment of wind power generation |
WO2019195678A1 (en) * | 2018-04-05 | 2019-10-10 | The Texas A&M University System | Synthesis of novel xylose free occidiofungin analogues and methods of using them |
CN113151112B (zh) * | 2021-05-24 | 2022-06-28 | 河南省科学院生物研究所有限责任公司 | 一株花生内生细菌洋葱伯克氏菌r-11及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030130121A1 (en) * | 1999-11-30 | 2003-07-10 | Berndt Gerhardson | Novel bacterial isolate and the preparation and use of its active metabolites |
EP1569955A2 (en) * | 2002-12-03 | 2005-09-07 | Sloan-Kettering Institute For Cancer Research | Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof |
US7345219B2 (en) * | 2003-01-31 | 2008-03-18 | The Board Of Trustees For The University Of Arkansas | Mitogen-activated protein kinase and method of use to enhance biotic and abiotic stress tolerance in plants |
DE602004010915T2 (de) * | 2003-07-22 | 2008-12-11 | Theravance, Inc., South San Francisco | Verwendung eines antimykotischen echinocandin-mittels in kombination mit einem antibakteriellen glycopeptid-mittel |
CA2571828A1 (en) * | 2004-05-21 | 2005-12-01 | Mpex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors and methods of treating bacterial infections |
-
2010
- 2010-05-25 US US12/800,922 patent/US20110136729A1/en not_active Abandoned
- 2010-05-26 WO PCT/US2010/001530 patent/WO2010138173A1/en active Application Filing
- 2010-05-26 DK DK10780921T patent/DK2435060T3/da active
- 2010-05-26 PT PT107809212T patent/PT2435060T/pt unknown
- 2010-05-26 KR KR1020117030475A patent/KR20120062644A/ko not_active Application Discontinuation
- 2010-05-26 CN CN201080023431XA patent/CN102448481A/zh active Pending
- 2010-05-26 HU HUE10780921A patent/HUE047339T2/hu unknown
- 2010-05-26 PL PL10780921T patent/PL2435060T3/pl unknown
- 2010-05-26 EP EP10780921.2A patent/EP2435060B1/en active Active
- 2010-05-26 JP JP2012513041A patent/JP2012528152A/ja active Pending
- 2010-05-26 ES ES10780921T patent/ES2757855T3/es active Active
-
2015
- 2015-07-22 US US14/806,121 patent/US10092622B2/en active Active
Non-Patent Citations (1)
Title |
---|
JPN6014039078; Biochemical and Biophysical Research Communications Vol.380, 20090306, P.328-332 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2019124410A1 (ja) * | 2017-12-21 | 2020-05-28 | 株式会社 サティス製薬 | 化粧料用原料とこれを配合してなる皮膚用化粧料 |
JP2021176892A (ja) * | 2017-12-21 | 2021-11-11 | 株式会社 サティス製薬 | 皮膚用化粧料用原料とこれを配合してなる皮膚用化粧料 |
JP7184394B2 (ja) | 2017-12-21 | 2022-12-06 | 株式会社 サティス製薬 | 皮膚用化粧料用原料とこれを配合してなる皮膚用化粧料 |
Also Published As
Publication number | Publication date |
---|---|
EP2435060B1 (en) | 2019-08-28 |
US20110136729A1 (en) | 2011-06-09 |
KR20120062644A (ko) | 2012-06-14 |
US20160008423A1 (en) | 2016-01-14 |
ES2757855T3 (es) | 2020-04-30 |
HUE047339T2 (hu) | 2020-04-28 |
WO2010138173A1 (en) | 2010-12-02 |
PT2435060T (pt) | 2019-12-05 |
US10092622B2 (en) | 2018-10-09 |
DK2435060T3 (da) | 2019-11-25 |
PL2435060T3 (pl) | 2020-03-31 |
CN102448481A (zh) | 2012-05-09 |
EP2435060A1 (en) | 2012-04-04 |
EP2435060A4 (en) | 2012-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10092622B2 (en) | Occidiofungin, a unique antifungal glycopeptide produced by a strain of Burkholderia contaminans | |
Lu et al. | Occidiofungin, a unique antifungal glycopeptide produced by a strain of Burkholderia contaminans | |
Brown et al. | New natural products as new leads for antibacterial drug discovery | |
Vicente et al. | Microbial natural products as a source of antifungals | |
Zhang et al. | New insights into membrane-active action in plasma membrane of fungal hyphae by the lipopeptide antibiotic bacillomycin L | |
Bassarello et al. | Tolaasins A− E, five new lipodepsipeptides produced by Pseudomonas tolaasii | |
Mandal et al. | Identification of an antifungal peptide from Trapa natans fruits with inhibitory effects on Candida tropicalis biofilm formation | |
Hossain et al. | New investigational antifungal agents for treating invasive fungal infections | |
Ehren et al. | Characterization of the cell wall of a mushroom forming fungus at atomic resolution using solid-state NMR spectroscopy | |
Hashimoto | Micafungin: a sulfated echinocandin | |
Lee et al. | Antifungal activity of Salvia miltiorrhiza against Candida albicans is associated with the alteration of membrane permeability and (1, 3)-β-D-glucan synthase activity | |
Ramirez et al. | Dilipid ultrashort tetrabasic peptidomimetics potentiate novobiocin and rifampicin against multidrug-resistant Gram-negative bacteria | |
Yang et al. | Sanxiapeptin, a linear pentapeptide from Penicillium oxalicum, inhibited the growth of citrus green mold | |
Jiang et al. | Integrating genomics and metabolomics for the targeted discovery of new cyclopeptides with antifungal activity from a marine-derived fungus Beauveria felina | |
Rautenbach et al. | An electrospray ionization mass spectrometry study on the “In Vacuo” hetero-oligomers formed by the antimicrobial peptides, surfactin and gramicidin S | |
Abdullah et al. | Ganoderma boninense mycelia for phytochemicals and secondary metabolites with antibacterial activity | |
Rautenbach et al. | Oligomerisation of tryptocidine C, a Trp-rich cyclodecapeptide from the antimicrobial tyrothricin complex | |
Gao et al. | Structural sequencing of oligopeptides aided by 1H iterative full-spin analysis | |
Arockianathan et al. | Recent status and advancements in the development of antifungal agents: highlights on plant and marine based antifungals | |
Schwan | Mushrooms: an untapped reservoir for nutraceutical antibacterial applications and antibacterial compounds | |
Sortino et al. | The role of natural products in discovery of new anti-infective agents with emphasis on antifungal compounds | |
Campos et al. | Methanolic extract of Mitracarpus frigidus inhibits filamentation and biofilm mode of growth from multidrug resistant Candida albicans | |
Ramesh et al. | A promising antifungal lipopeptide from Bacillus subtilis: its characterization and insight into the mode of action | |
Komathy | Protein profiling of Candida albicans planktonic and biofilm cultures upon exposure to Aureobasidin/Komathy Munusamy | |
Munusamy | Protein Profiling of Candida albicans Planktonic and Biofilm Cultures Upon Exposure to Aureobasidin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130525 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130525 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140916 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141216 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150609 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150905 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151008 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151208 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160308 |